Evidence map›Paper›PMID 25664986›Full record

ArticlePloS one2015

Viscum album-mediated COX-2 inhibition implicates destabilization of COX-2 mRNA.

Chaitrali Saha, Pushpa Hegde, Alain Friboulet, Jagadeesh Bayry, Srinivas V Kaveri

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. The Anti-Inflammatory Activity ofPlants (Basel, Switzerland) · 2023
    Review
  4. RETRACTED: Orientin, a Bio-Flavonoid fromPharmaceuticals (Basel, Switzerland) · 2022
    Article
  5. Review
  6. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies.Evidence-based complementary and alternative medicine : eCAM · 2019
    Review
  7. Experimental and therapeutic medicine · 2017
    Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Chaitrali SahaInstitut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, France; Université de Technologie de Compiègne, UMR CNRS 6022, Compiègne, France; Centre de Recherche des Cordeliers, Equipe-Immunopathology and therapeutic immunointervention, Paris, France.
Pushpa HegdeInstitut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, France; Université de Technologie de Compiègne, UMR CNRS 6022, Compiègne, France; Centre de Recherche des Cordeliers, Equipe-Immunopathology and therapeutic immunointervention, Paris, France.
Alain FribouletUniversité de Technologie de Compiègne, UMR CNRS 6022, Compiègne, France.
Jagadeesh BayryInstitut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, France; Centre de Recherche des Cordeliers, Equipe-Immunopathology and therapeutic immunointervention, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Paris, France.
Srinivas V KaveriInstitut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, France; Centre de Recherche des Cordeliers, Equipe-Immunopathology and therapeutic immunointervention, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Paris, France.
Centre National de la Recherche Scientifique · FRSorbonne Paris Cité · FRSorbonne Université · FRUniversité de Technologie de Compiègne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extensive use of Viscum album (VA) preparations in the complementary therapy of cancer and in several other human pathologies has led to an increasing number of cellular and molecular approaches to explore the mechanisms of action of VA. We have recently demonstrated that, VA preparations exert a potent anti-inflammatory effect by selectively down-regulating the COX-2-mediated cytokine-induced secretion of prostaglandin E2 (PGE2), one of the important molecular signatures of inflammatory reactions. In this study, we observed a significant down-regulation of COX-2 protein expression in VA-treated A549 cells however COX-2 mRNA levels were unaltered. Therefore, we hypothesized that VA induces destabilisation of COX-2 mRNA, thereby depleting the available functional COX-2 mRNA for the protein synthesis and for the subsequent secretion of PGE2. To address this question, we analyzed the molecular degradation of COX-2 protein and its corresponding mRNA in A549 cell line. Using cyclohexamide pulse chase experiment, we demonstrate that, COX-2 protein degradation is not affected by the treatment with VA whereas experiments on transcriptional blockade with actinomycin D, revealed a marked reduction in the half life of COX-2 mRNA due to its rapid degradation in the cells treated with VA compared to that in IL-1β-stimulated cells. These results thus demonstrate that VA-mediated inhibition of PGE2 implicates destabilization of COX-2 mRNA.

Indexed as

Viscum albumCell Line, TumorCyclooxygenase 2Cyclooxygenase 2 InhibitorsDown-RegulationHumansPlant PreparationsRNA, MessengerRNA StabilityCyclooxygenase 2Cyclooxygenase 2 InhibitorsPlant PreparationsPTGS2 protein, humanRNA, Messenger

Identifiers

PMID25664986
PMCPMC4321838
OpenAlexW2115414184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.